
==== Front
Dig Dis Sci
Dig Dis Sci
Digestive Diseases and Sciences
0163-2116
1573-2568
Springer US New York

38987444
8499
10.1007/s10620-024-08499-2
Original Article
Burden of Portal Hypertension Complications Is Greater in Liver Transplant Wait-Listed Registrants with End-Stage Liver Disease and Type 2 Diabetes
Yakubu Idris 1
Flynn Sean 2
Khan Hiba 2
Nguyen Madison 2
Razzaq Rehan 2
Patel Vaishali 3
Kumaran Vinay 4
Sharma Amit 4
Siddiqui Mohammad Shadab mohammad.siddiqui@vcuhealth.org

35
1 https://ror.org/02nkdxk79 grid.224260.0 0000 0004 0458 8737 Department of Pharmacy, Virginia Commonwealth University (VCU), Richmond, USA
2 https://ror.org/02nkdxk79 grid.224260.0 0000 0004 0458 8737 Department of Internal Medicine, Virginia Commonwealth University (VCU), Richmond, USA
3 https://ror.org/02nkdxk79 grid.224260.0 0000 0004 0458 8737 Division of Gastroenterology and Hepatology, Virginia Commonwealth University School of Medicine, Richmond, USA
4 grid.224260.0 0000 0004 0458 8737 Division of Transplant Surgery, VCU, Richmond, USA
5 https://ror.org/02nkdxk79 grid.224260.0 0000 0004 0458 8737 Virginia Commonwealth University, 1200 East Broad Street, P.O. Box 980204, Richmond, VA 23298 USA
10 7 2024
10 7 2024
2024
69 9 35543562
23 3 2024
11 5 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Background and Aims

Impact of type 2 diabetes mellitus (T2DM) in patients with end-stage liver disease (ESLD) awaiting liver transplantation (LT) remains poorly defined. The objective of the present study is to evaluate the relationship between T2DM and clinical outcomes among patients with LT waitlist registrants. We hypothesize that the presence of T2DM will be associated with worse clinical outcomes.

Methods

593 patients adult (age 18 years or older) who were registered for LT between 1/2010 and 1/2017 were included in this retrospective analysis. The impact of T2DM on liver-associated clinical events (LACE), survival, hospitalizations, need for renal replacement therapy, and likelihood of receiving LT were evaluated over a 12-month period. LACE was defined as variceal hemorrhage, hepatic encephalopathy, and ascites. Kaplan–Meier and Cox regression analysis were used to determine the association between T2DM and clinical outcomes.

Results

The baseline prevalence of T2DM was 32% (n = 191) and patients with T2DM were more likely to have esophageal varices (61% vs. 47%, p = 0.002) and history of variceal hemorrhage (23% vs. 16%, p = 0.03). The presence of T2DM was associated with increased risk of incident ascites (HR 1.91, 95% CI 1.11, 3.28, p = 0.019). Patients with T2DM were more likely to require hospitalizations (56% vs. 49%, p = 0.06), hospitalized with portal hypertension-related complications (22% vs. 14%; p = 0.026), and require renal replacement therapy during their hospitalization. Patients with T2DM were less likely to receive a LT (37% vs. 45%; p = 0.03). Regarding MELD labs, patients with T2DM had significantly lower bilirubin at each follow-up; however, no differences in INR and creatinine were noted.

Conclusion

Patients with T2DM are at increased risk of clinical outcomes. This risk is not captured in MELD score, which may potentially negatively affect their likelihood of receiving LT.

Supplementary Information

The online version contains supplementary material available at 10.1007/s10620-024-08499-2.

Keywords

Portal hypertension
End-stage liver disease
Decompensated cirrhosis
Liver associated clinical events
Waitlist mortality
issue-copyright-statement© Springer Science+Business Media, LLC, part of Springer Nature 2024
==== Body
pmcIntroduction

Type 2 Diabetes mellitus (T2DM) is associated with increased risk of fibrosis progression and metabolic complications in patients with non-cirrhotic chronic liver disease, particularly in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) [1–4]. However, the published literature evaluating the impact of T2DM in patients with cirrhosis is limited and has produced mixed results [5–7]. The projected increase in the prevalence of both T2DM [8] and cirrhosis [9] over the next decade underscores the importance of better understanding the interaction between them as they impact both liver-associated clinical events (LACE) and non-LACE in this patient population. Furthermore, as more patients develop cirrhosis and progress to end-stage liver disease (i.e., decompensated cirrhosis), it is imperative to know how T2DM may affect clinical outcomes in these patients as they await liver transplantation (LT) [10].

The published literature evaluating the impact of diabetes in patients with cirrhosis is limited by relatively small sample size [11], and mostly constitutes of patients with viral hepatitis as the predominant etiology of cirrhosis which is not reflective of current trends that favors alcohol and MAFLD as the leading causes of cirrhosis [12]. Furthermore, the existing literature lacks heterogeneity in patient population that is inclusive of both patients with compensated and decompensated cirrhosis [13], thereby, potentially diffusing the effect size as the risk of decompensation is relatively low in patients with compensated cirrhosis [14]. There is also a lack of studies that have evaluated the impact of diabetes on morbidity and mortality in patients awaiting LT to better define how T2DM affects key transplant-related parameters such as waitlist mortality, likelihood of receiving LT and impact on metabolic complications such as cardiovascular disease and renal function.

As the impact of T2DM in patients with end-stage liver disease on LT waitlist is not known, we conducted the current study to evaluate the relationship between T2DM and clinical outcomes among patients with end-stage liver disease, undergoing LT evaluation. We hypothesized that the presence of T2DM will be associated with increased LACEs, metabolic complications, and reduced likelihood of receiving a LT. This hypothesis was tested in a large retrospective cohort of LT waitlist registrants using patient-level data.

Materials and Methods

The current study is a retrospective analysis of patients who were registered for LT waitlist at Virginia Commonwealth University (VCU). The study was approved by the institutional review board. All authors reviewed and approved the manuscript prior to submission.

Study Cohort

All adult patients, aged 18 years or older, who were registered on LT waitlist at Virginia Commonwealth University (VCU) between 1/2010 and 1/2017 were included in the analysis. Patients who were evaluated but not registered on the LT waitlist were excluded since the main objective of the current study was to evaluate the impact of T2DM on waitlist complications in LT candidates. Patients listed for dual organ transplants (i.e., liver-kidney or liver-heart) were also excluded. As part of the LT evaluation, all patients underwent detailed cardiovascular evaluation which included 2D-echocardiography and coronary artery disease assessment, which could include coronary angiography [15–17].

Follow-Up and Clinical Events

All patients were followed at 3-month intervals where routine bio-clinical data were collected, such as medical history, medication changes, laboratory, and vital signs. Patients also had their medical charts reviewed for any clinical events, which were characterized as LACE or non-LACE. LACE events included variceal hemorrhage, hepatic encephalopathy, and ascites. Additional complications of cirrhosis included development of varices, hepatic hydrothorax, hepatopulmonary syndrome, portopulmonary hypertension, and spontaneous bacterial peritonitis (SBP) [18]. Development of hepatocellular carcinoma (HCC) was not evaluated as a clinical outcome as HCC is a significant reason for LT waitlist registration and development of HCC, while waiting for LT is relatively uncommon, thereby, precluding significant statistical analysis [19]. Non-LACE parameters evaluated included hospitalization-related parameters that included number of hospitalizations, intensive care unit (ICU) level care, need for mechanical ventilation, and initiation of renal replacement therapy. The cause of hospitalization was enumerated as hepatic decompensation, infection, renal failure, and cardiovascular events including myocardial infarction, stroke, and cardiovascular death.

Definitions

Patients were considered to have T2DM if they had a medical diagnosis of T2DM, were taking exogenous insulin, hypoglycemic agents, or had HbA1c > 6.5%. Similarly, diagnosis of hepatic decompensation was extracted from the chart and included ascites, hepatic hydrothorax, esophageal varices, acute variceal hemorrhage (AVH), spontaneous bacterial peritonitis (SBP), and hepatic encephalopathy (HE).

Statistical Analysis

Categorical variables are reported as frequency and percentages, whiles continuous variables were reported as mean ± standard deviation (SD) if normally distributed and median with IQR if non-normal distribution. As this patient population consists mainly of patients with end-stage liver disease, most of the patients had already experienced a hepatic decompensating event. Thus, we first evaluated the relationship between likelihood of developing incident portal hypertension-related complications (i.e., incident ascites in patients without ascites at time of LT evaluation) via Kaplan-Meyer analysis and Cox regression in patients with and without T2DM. Regression analysis was adjusted for age, gender [male], etiology of liver disease, and baseline model for end-stage liver disease (MELD) score.

In the next analysis, the impact of T2DM on (1) individual cirrhosis-associated complications (2) hospitalizations (3) waitlist mortality and (4) likelihood of receiving LT was evaluated. To gain a deeper understanding on how the presence of T2DM might affect MELD score, the components of MELD score (creatinine, INR, bilirubin) were plotted over time, stratified according to T2DM status. In this analysis, patients who received a LT were excluded after the LT. Analysis of variance (ANOVA) and Student’s t test to test for differences in normally distributed continuous variables, Mann–Whitney U test for non-normally distributed continuous variables, and Chi-square or Fisher’s exact test for categorical variables to compare groups. A nominal p value of < 0.05 was considered statistically significant. The analysis was performed with the SPSS (IBM Inc., Cary, NC).

Results

Baseline Characteristics of Study Cohort

A total of 593 patients met inclusion criteria and were included in our final analysis (Table 1). The mean age of the cohort was 53 ± 10 years and consisted mainly of men (n = 382, 64%) and non-Hispanic whites (n = 430, 73%). The most common etiology of cirrhosis was Hepatitis C (37%), followed by alcohol-induced (29%) and MASH (17%). At baseline, T2DM was present in 192 (32%) of patients and of these, 73 patients were on exogenous insulin. The baseline mean HbA1c was 6.0 ± 1.84 and the fasting blood glucose was 126 ± 57.74 mg/dL. The mean MELD score at time of LT waitlist registration was 15.06 ± 6.95. The prevalence of ascites, hepatic encephalopathy, and history of variceal hemorrhage at baseline was 64%, 53%, and 17%, respectively.Table 1 Baseline characteristics of the entire cohort

	Entire cohort
(n = 593)	
Demographics		
 Age (years)	53.53 ± 9.61	
 Gender (%)		
  Males	382 (64.4%)	
  Females	211 (35.6%)	
 Ethnicity		
  Non-Hispanic Caucasian	432 (72.8%)	
  African Americans	134 (22.6%)	
  Hispanic	12 (2%)	
  Asian	11 (1.9%)	
  Other	4 (0.7%)	
Etiology of liver disease		
 Autoimmune hepatitis (%)	26 (4.4%)	
 Ethanol (%)	144 (29.3%)	
 Hepatitis C (%)	217 (36.6%)	
 Metabolic dysfunction-associated steatohepatitis (%)	101 (17%)	
 Primary biliary cholangitis (%)	8 (1.3%)	
 Primary sclerosing cholangitis (%)	41 (6.9%)	
 Other (%)	56 (9.4%)	
Medical comorbidities		
 Coronary artery disease (%)	127 (21.4%)	
 Dyslipidemia (%)	113 (19.1%)	
 Hypertension (%)	261 (44%)	
 Body mass index (kg/m2)	29.78 ± 6.79	
 Obesity (%)	254 (42.8%)	
 End-stage renal disease	45 (7.6%)	
Portal hypertension		
 Ascites (%)	383 (64.6%)	
 Hepatic hydrothorax (%)	31 (5.2%)	
 Hepatic encephalopathy (%)	316 (53.3%)	
 Varices present (%)	290 (48.9%)	
 History of variceal hemorrhage (%)	103 (17.4%)	
 Hepatopulmonary syndrome (%)	10 (1.7%)	
 Portopulmonary hypertension (%)	11 (1.9%)	
 Hepatorenal syndrome (%)	29 (4.9%)	
 Hepatocellular carcinoma (%)	72 (12.1%)	
 Spontaneous bacterial peritonitis (%)	45 (7.6%)	
Laboratory values		
 Blood urea nitrogen (mg/dL)	19.70 ± 14.1	
 Creatinine (mg/dL)	1.34 ± 1.50	
 Sodium (mg/dL)	136.30 ± 4.82	
 International normalized ratio	1.51 ± 0.50	
 Hemoglobin (mg/dL)	11.36 ± 2.18	
 Platelets (× 109/L)	110.33 ± 75.71	
 Alanine aminotransferase (IU/L)	59.30 ± 59.05	
 Aspartate aminotransferase (IU/L)	91.73 ± 86.51	
 Alkaline phosphatase (IU/L)	188 ± 161	
 Total bilirubin (mg/dL)	3.90 ± 4.63	
 Direct bilirubin (mg/dL)	2.39 ± 3.64	

Patients with T2DM were older (57 ± 7 vs. 52 ± 10 years, p < 0.001) and more likely to be males (70% vs 61%) (Supplemental Table 1). The BMI was 31 ± 6.6 kg/m2 in patients with T2DM compared to 29.2 ± 6.8 kg/m2 patients without T2DM (p = 0.004). Significant differences in prevalence of etiologies of end-stage liver disease requiring LT were noted in patients T2DM, when compared to patients without T2DM (Supplemental Table 1). Metabolic comorbidities, such as coronary artery disease, hypertension, dyslipidemia, and obesity, were also more common in patients with T2DM.

Relationship Between T2DM and Portal Hypertension at Baseline

Patients with T2DM were more likely to have esophageal varices (61% vs. 47%, p = 0.002) and history of acute variceal hemorrhage (23% vs. 16%, p = 0.03) (Fig. 1). The presence of other complications of cirrhosis including hepatic encephalopathy, ascites, SBP, and hepatic hydrothorax was similar in patients with and without T2DM at baseline. Baseline MELD scores were similar between the two cohorts; however, patients with T2DM had lower total bilirubin when compared to patients without T2DM (3.01 ± 3.59 vs. 4.45 ± 5.24 mg/dL; p < 0.001). No other differences in laboratory values between the two cohorts were noted.Fig. 1 Baseline burden of portal hypertension stratified according to the presence of type 2 diabetes

In unadjusted analysis, the presence of T2DM was significantly associated with the presence of varices (OR 1.77, 95% CI 1.23, 2.53, p = 0.002) and history of acute variceal hemorrhage (OR 1.57, 95% CI 1.02, 2.43, p = 0.04). An association between hepatic hydrothorax and diabetes was noted; however, this did not reach the significance threshold (OR 2.03, 95% CI 0.98, 4.20, p = 0.05). In adjusted analysis, the relationship between T2DM and portal hypertension-related complications of the presence of varices (OR 1.51, 95% CI 1.03, 2.20, p = 0.03) and hepatic hydrothorax (OR 2.53, 95% CI 1.154, 5.54, p = 0.02) remained significant. The association between T2DM and HPS was noted; however, this did not reach significance (p = 0.08).

Impact of T2DM on Developing Hepatic Clinical Outcomes

The impact of T2DM on incident risk of hepatic decompensation was investigated via Cox regression. Patients with T2DM were more likely to develop incident ascites after 12 months of follow-up when compared to patients without T2DM (HR 1.91, 95% CI 1.11, 3.28, p = 0.019) (Fig. 2A). No statistically significant association between the presence of T2DM and likelihood of developing new esophageal varices, acute variceal hemorrhage, HE, SBP, and hepatic hydrothorax was noted (Fig. 2B–F).Fig. 2 Impact of type 2 diabetes mellitus (T2DM) on incidence of developing portal hypertension-related outcomes. Patients with T2DM were more likely to develop ascites (A); however, T2DM did not affect likelihood of developing varices, acute variceal hemorrhage (AVH), hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP) or hepatic hydrothorax (B–F, respectively)

Patients with T2DM were more likely to require hospitalizations (56% vs. 49%) over 12 months of follow-up; however, this did not reach statistical significance (p = 0.06) (Fig. 3A). The mean number hospitalization between patients with and without T2DM was similar (2.0 ± 1.2 vs. 1.8 ± 1.1; p = 0.21) over the 12-month period. However, patients with T2DM were more likely to require renal replacement therapy during their hospitalization compared to patients without T2DM (Fig. 3B). Patients with diabetes were more likely to be hospitalized with portal hypertension-related complications (22% vs. 14%; p = 0.026). During these hospitalizations, diabetes did not impact the probability of Intensive care unit (ICU) admission or mechanical ventilation (Fig. 3C, D).Fig. 3 Impact of type 2 diabetes mellitus (T2DM) on likelihood of hospitalization and associated complications. While T2DM status did not affect likelihood of hospitalization (A), patients with T2DM were more likely to initiated hemodialysis during their hospitalization (B). No association between intensive care unit (ICU) admission (C) or need mechanical ventilation (D) and T2DM were noted

Impact of T2DM on Transplant Related Outcomes

Patients with T2DM were more likely to die (35% vs. 27%; p = 0.03); however, on survival analysis, survival rates between patients with and without T2DM were similar (Fig. 4A). Patients with T2DM were less likely to receive a LT (37% vs. 45%; p = 0.04) when compared to cirrhosis patients without T2DM (Fig. 4B). When components of MELD score (INR, bilirubin, and creatinine) were plotted over time, patients with T2DM were noted to have significantly lower serum bilirubin (Fig. 4C). No differences in INR and creatine over time were noted over time (Fig. 4D, E). Finally, liver-related causes of mortality were similar in patient with and without diabetes (Fig. 4F).Fig. 4 Interplay between type 2 diabetes mellitus (T2DM) and liver transplant (LT) metrics. While overall survival was similar between patients with and without T2DM (A), patients with T2DM were less likely to receive a liver transplantation (B). Trend in international normalized ratio (INR; C), total bilirubin (D), and creatinine (E) revealed that patients with T2DM have lower serum bilirubin than patients without T2DM. Causes of mortality are enumerated in F

Discussion

The overall prevalence of diabetes is increasing rapidly [20], particularly among patients with chronic liver disease and cirrhosis, underscoring the importance of better understanding the interaction between them as driver of hepatic decompensation and clinical outcomes [21]. The present study expands on the published literature by demonstrating that patients with T2DM and end-stage liver disease have higher morbidity.

Study Findings in the Context of Published Literature

The published literature evaluating the impact of T2DM on liver-associated clinical events (LACE) is limited, particularly in patients with end-stage liver disease. Moreover, the literature is limited by relatively small sample size, exclusion of patient with known history of decompensated cirrhosis, and lack of association between T2DM and liver transplantation [13, 14]. The present study designed to overcome these limitations demonstrates significantly higher burden of portal hypertension in patients with end-stage liver disease and T2DM. The study corroborates prior reported data from studies with smaller sample size that also demonstrated higher portal hypertension-related burden in patients with T2DM [10, 22–24]. While the association between compensated cirrhosis and T2DM has been reported previously [25, 26], the current study expands on this by demonstrating the patients with T2DM and end-stage liver disease at significantly higher risk for liver-related morbidity and mortality. Furthermore, patients with T2DM were more likely to develop incident complications of portal hypertension, notably ascites, acute variceal hemorrhage, or varices over the study period. While historically, T2DM is over-represented in MASH (vs. other etiologies of cirrhosis). However, in the current cohort of patients with T2DM, the proportion of patients with MASH cirrhosis is slightly higher, but similar to the proportion of patients with HCV, the two most common etiologies of cirrhosis in the cohort. This provides preliminary data on how T2DM might drive clinical outcomes irrespective of the etiology of chronic liver disease. Furthermore, as MASH is the leading indication for LT in women and elderly and poised to be the leading indication among all potential LT recipients, these findings are generalizable to what a typical LT population will be in the near future.

No significant differences with regard to hospitalizations, ICU stay, or survival were noted in patients with and without T2DM. As the baseline risk of decompensation, hospitalization, and death is higher in the study cohort, it is not surprising that no significant differences in these outcomes were noted at study end. Furthermore, the causes of mortality were similar in patients with and without T2DM and expectedly, hepatic causes were the leading cause of mortality. Patients with T2DM were more likely to require renal replacement therapy during their hospitalizations. This might potentially be due to the presence of underlying chronic kidney disease that patients with T2DM are higher risk for primed them to developing renal injury that required renal replacement therapy [27]. Interestingly, serum creatinine at baseline was similar between the two cohorts suggesting the renal susceptibility may not be fully captured by commonly used renal parameters such as serum creatinine. Moreover, creatinine is known to be affected by muscle mass and sarcopenic patients have a reduced muscle mass. Given that sarcopenia is more prevalent in patients with T2DM, the use of serum creatinine and creatinine-based eGFR in this population may overestimate renal function. These findings underscore the importance of developing and validating tools that better evaluate the interaction between muscle mass to provide a better risk adjustment model. While some studies have reported reduced survival in patients with T2DM, other studies do not corroborate these findings [5, 10, 11, 26].

Impact of Study Findings on Clinical Practice

Patients with T2DM were less likely to receive LT over study duration when compared to patients without T2DM. As the observed survival and morbidity were similar in the two cohorts, a possible explanation for these findings is patients with DM may develop co-morbid conditions that lead to inactivation such as infections therefore disadvantaging them on the LT waitlist. While patients with T2DM were noted to have lower serum bilirubin, which persisted over the duration of the study cohort. However, other contributors of MELD score including INR and serum creatinine were not significantly different between the two cohorts. As the prevalence of chronic kidney disease is higher in patients with T2DM, lack of differences in renal function-related parameters (creatinine, blood urea nitrogen, eGFR) in the study cohort can potentially be explained by other competing factors such as diuretic use, HRS, and dehydration, that can lead to similar serum creatinine levels in patients with and without T2DM. The combined observations demonstrating higher baseline prevalence and incident risk of portal hypertension-related complications and lower probability of LT suggest that the MELD score alone underestimates the morbidity in patients with T2DM. Changes to MELD score calculation have been proposed over the years (i.e., MELDNa, MELD 3.0) with the overarching goal of improving organ allocations; however, how these scores might perform in patients with T2DM is not as well established. Given the study findings, it might be prudent to evaluate the relationship between T2DM and MELD score to improve outcomes in LT waitlisted patients. While the findings of this study are preliminary, it is important to confirm them in well-designed prospective studies to allow for better risk stratification of patients with T2DM undergoing LT evaluation. Recognizing this increased risk is fundamental to developing risk mitigation strategies to not only improve clinical outcomes of patients awaiting LT.

Study Strengths and Limitations

The current study is the largest study to date evaluating impact of T2DM on patients with end-stage liver disease undergoing LT evaluation. The clinical outcomes were carefully adjudicated and the study design evaluated outcomes important in clinical management including both hepatic and non-hepatic complications. The study is retrospective in design; however, as there are no data on T2DM among potential LT waitlist registrants, this study provides foundational data for study design and sample size determination for future prospective studies. The impact of diabetes treatment was not evaluated but will be difficult to do so in a retrospective study as hospitalizations, decompensation (i.e., renal failure) has the potential to not only change the type of hypoglycemic agents but also the intensity. Thus, a well-designed prospective study that incorporates the complexity of this patient population is necessary to better evaluate the relationship between type and intensity of hypoglycemic agents in patients with end-stage liver disease. The impact of glycemic control on clinical outcomes was not evaluated. As patients with end-stage liver disease are at higher risk for blood loss (bleeding, hemolysis) and may require blood transfusions, HbA1c may not be reliable. Serum fructosamine levels may provide more insight [28]; however, these are not collected as part of standard of care and thus could not be evaluated in this retrospective study. Given the limitations of classic measures of insulin resistance (i.e., fasting glucose and HbA1c) in this population, the potential impact of glycemic control and insulin resistance on clinical outcomes requires well-designed prospective studies with glucose tolerance test (clamp vs. frequent sampling) and a priori defined clinical outcomes are necessary. Moreover, such an approach can also lead to validation and development of better point of care testing (i.e., HOMA-IR, OGTT, etc.) to assess insulin resistance in this challenging patient population. Finally, while an association between RRT and T2DM was noted, the current study due to its retrospective study design is not able to provide a deeper understanding of these findings. Well-designed prospective studies are necessary to fully understand such an association.

In summary, T2DM in patients with end-stage liver disease is associated with increased morbidity and may negatively affect likelihood of receiving a LT. Additional studies are necessary to confirm these study findings and develop clinical strategies to improve outcomes in this patient population.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 19 kb)

Author's contribution

Conceptualization: IY, MSS, VP, AS, VK, data collection: SF, HK, MN, RR, statistical analysis: IY, MSS, manuscript preparation: IY, SF, MSS, critical revision: all authors.

Data availability

Data, analytic methods, and study materials will or will not be made available to other researchers.

Declarations

Conflict of interest

The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. MSS: AMRA, NovoNordisk. IY: Takeda Pharmaceuticals (Consultant). None: SF, TA, VP, VK, AS.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Idris Yakubu and Sean Flynn have contributed equally to this work.
==== Refs
References

1. Alexopoulos AS Crowley MJ Wang Y Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease Hepatology 2021 74 1220 1233 10.1002/hep.31806 33724511
Alexopoulos AS, Crowley MJ, Wang Y et al. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology 2021;74:1220–1233.33724511
2. McPherson S Anstee QM Changing epidemiology of chronic liver disease among ethnic groups in the United States Hepatology 2016 64 1843 1846 10.1002/hep.28783 27533477
McPherson S, Anstee QM. Changing epidemiology of chronic liver disease among ethnic groups in the United States. Hepatology 2016;64:1843–1846.27533477
3. Siddiqui MS Cheang KL Luketic VA Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (beta-Cell) Function Dig Dis Sci 2015 60 2529 2537 10.1007/s10620-015-3627-7 25784075
Siddiqui MS, Cheang KL, Luketic VA et al. Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (beta-Cell) Function. Dig Dis Sci 2015;60:2529–2537. 10.1007/s10620-015-3627-7.25784075
4. Angulo P Kleiner DE Dam-Larsen S Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease Gastroenterology 2015 149 389 97 e10 10.1053/j.gastro.2015.04.043 25935633
Angulo P, Kleiner DE, Dam-Larsen S et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015;149:389–97 e10.25935633
5. Quintana JO Garcia-Compean D Gonzalez JA The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study Annals of hepatology 2011 10 56 62 10.1016/S1665-2681(19)31588-1 21301011
Quintana JO, Garcia-Compean D, Gonzalez JA et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Annals of hepatology 2011;10:56–62.21301011
6. Nishida T Tsuji S Tsujii M Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis Am J Gastroenterol 2006 101 70 75 10.1111/j.1572-0241.2005.00307.x 16405536
Nishida T, Tsuji S, Tsujii M et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006;101:70–75.16405536
7. Berman K Tandra S Forssell K Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011 9 254 259 10.1016/j.cgh.2010.10.035 21092762
Berman K, Tandra S, Forssell K et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011;9:254–259.21092762
8. Hossain P Kawar B El Nahas M Obesity and diabetes in the developing world–a growing challenge N Engl J Med 2007 356 213 215 10.1056/NEJMp068177 17229948
Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world–a growing challenge. N Engl J Med 2007;356:213–215.17229948
9. Estes C Razavi H Loomba R Younossi Z Sanyal AJ Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease Hepatology 2018 67 123 133 10.1002/hep.29466 28802062
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123–133.28802062
10. Elkrief L Chouinard P Bendersky N Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C Hepatology 2014 60 823 831 10.1002/hep.27228 24841704
Elkrief L, Chouinard P, Bendersky N et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology 2014;60:823–831.24841704
11. Bianchi G Marchesini G Zoli M Bugianesi E Fabbri A Pisi E Prognostic significance of diabetes in patients with cirrhosis Hepatology 1994 20 119 125 8020880
Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994;20:119–125.8020880
12. Sangiovanni A Prati GM Fasani P The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients Hepatology 2006 43 1303 1310 10.1002/hep.21176 16729298
Sangiovanni A, Prati GM, Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43:1303–1310.16729298
13. Moreau R Delegue P Pessione F Clinical characteristics and outcome of patients with cirrhosis and refractory ascites Liver international: official journal of the International Association for the Study of the Liver 2004 24 457 464 10.1111/j.1478-3231.2004.0991.x 15482343
Moreau R, Delegue P, Pessione F et al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver international: official journal of the International Association for the Study of the Liver 2004;24:457–464.15482343
14. D'Amico G Garcia-Tsao G Pagliaro L Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies Journal of hepatology 2006 44 217 231 10.1016/j.jhep.2005.10.013 16298014
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. Journal of hepatology 2006;44:217–231.16298014
15. Patel SS Lin FP Rodriguez VA The relationship between coronary artery disease and cardiovascular events early after liver transplantation Liver international : official journal of the International Association for the Study of the Liver 2019 39 1363 1371 10.1111/liv.14092 30848862
Patel SS, Lin FP, Rodriguez VA et al. The relationship between coronary artery disease and cardiovascular events early after liver transplantation. Liver international : official journal of the International Association for the Study of the Liver 2019;39:1363–1371.30848862
16. Patel SS Guzman LA Lin FP Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation Liver Transpl 2018 24 872 880 10.1002/lt.25067 29624871
Patel SS, Guzman LA, Lin FP et al. Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation. Liver Transpl 2018;24:872–880.29624871
17. Patel SS Nabi E Guzman L Coronary artery disease in decompensated patients undergoing liver transplantation evaluation Liver Transpl 2018 24 333 342 10.1002/lt.25012 29328556
Patel SS, Nabi E, Guzman L et al. Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. Liver Transpl 2018;24:333–342.29328556
18. Garcia-Tsao G Abraldes JG Berzigotti A Bosch J Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases Hepatology 2017 65 310 335 10.1002/hep.28906 27786365
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65:310–335.27786365
19. Finotti M Vitale A Volk M Cillo U A 2020 update on liver transplant for hepatocellular carcinoma Expert Rev Gastroenterol Hepatol 2020 14 885 900 10.1080/17474124.2020.1791704 32662680
Finotti M, Vitale A, Volk M, Cillo U. A 2020 update on liver transplant for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:885–900.32662680
20. Cannon A Handelsman Y Heile M Shannon M Burden of Illness in Type 2 Diabetes Mellitus J Manag Care Spec Pharm 2018 24 S5 S13 30156443
Cannon A, Handelsman Y, Heile M, Shannon M. Burden of Illness in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm 2018;24:S5–S13.30156443
21. Younossi ZM Gramlich T Matteoni CA Boparai N McCullough AJ Nonalcoholic fatty liver disease in patients with type 2 diabetes Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2004 2 262 265 10.1016/S1542-3565(04)00014-X 15017611
Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2004;2:262–265.15017611
22. Sigal SH Stanca CM Kontorinis N Bodian C Ryan E Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis Am J Gastroenterol 2006 101 1490 1496 10.1111/j.1572-0241.2006.00649.x 16863551
Sigal SH, Stanca CM, Kontorinis N, Bodian C, Ryan E. Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. Am J Gastroenterol 2006;101:1490–1496.16863551
23. Kalaitzakis E Olsson R Henfridsson P Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis Liver international : official journal of the International Association for the Study of the Liver 2007 27 1194 1201 10.1111/j.1478-3231.2007.01562.x 17919230
Kalaitzakis E, Olsson R, Henfridsson P et al. Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. Liver international : official journal of the International Association for the Study of the Liver 2007;27:1194–1201.17919230
24. Rao Kondapally Seshasai S Kaptoge S Thompson A Diabetes mellitus, fasting glucose, and risk of cause-specific death N Engl J Med 2011 364 829 841 10.1056/NEJMoa1008862 21366474
Rao Kondapally Seshasai S, Kaptoge S, Thompson A et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829–841.21366474
25. Jeon HK Kim MY Baik SK Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage Dig Dis Sci 2013 58 3335 3341 10.1007/s10620-013-2802-y 23912248
Jeon HK, Kim MY, Baik SK et al. Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage. Dig Dis Sci 2013;58:3335–3341. 10.1007/s10620-013-2802-y.23912248
26. Liu TL Trogdon J Weinberger M Fried B Barritt AS Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis Dig Dis Sci 2016 61 3335 3345 10.1007/s10620-016-4261-8 27480088
Liu TL, Trogdon J, Weinberger M, Fried B, Barritt AS. Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis. Dig Dis Sci 2016;61:3335–3345. 10.1007/s10620-016-4261-8.27480088
27. Calmus Y Conti F Cluzel P Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: effects on long-term renal function after liver transplantation Journal of hepatology 2012 57 572 576 10.1016/j.jhep.2012.04.028 22612996
Calmus Y, Conti F, Cluzel P et al. Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: effects on long-term renal function after liver transplantation. Journal of hepatology 2012;57:572–576.22612996
28. Trenti T Cristani A Cioni G Pentore R Mussini C Ventura E Fructosamine and glycated hemoglobin as indices of glycemic control in patients with liver cirrhosis Ric Clin Lab 1990 20 261 267 10.1007/BF02900711 2075378
Trenti T, Cristani A, Cioni G, Pentore R, Mussini C, Ventura E. Fructosamine and glycated hemoglobin as indices of glycemic control in patients with liver cirrhosis. Ric Clin Lab 1990;20:261–267.2075378
